Volume 7, Issue 4 (July - August 2022)
J Obstet Gynecol Cancer Res 2022, 7(4): 314-322 |
Back to browse issues page
Dariush Abtahi * 
1, Mehrdad Feizi2 , Shahram Sayadi3 , Ardeshir Tajbakhsh3 , Samira Abbaspour4, Sara Salarian3 , Alireza Mirkheshti3 , Elham Memary3
1, Mehrdad Feizi2 , Shahram Sayadi3 , Ardeshir Tajbakhsh3 , Samira Abbaspour4, Sara Salarian3 , Alireza Mirkheshti3 , Elham Memary3
1- Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , drmemary@gmail.com
2- Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Functional Neurosurgery Research Center, Shohada-ye Tajrish, Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2- Department of Pharmacology and Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Anesthesiology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4- Functional Neurosurgery Research Center, Shohada-ye Tajrish, Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (1140 Views)
Background and Objective: This study was performed to determine and compare the ED90 of prophylactic oxytocin (OX) infusion after delivery of the placenta during cesarean section (CS) in low- and high-risk parturients for uterine atony.
Methods: This experimental study was a single-blind and dose-response study using a 9:1 biased-coin sequential allocation method to estimate the ED90 of prophylactic infusion of OX in women with high and low risk for uterine atony who underwent CS. The total administrated OX dose of each patient was determined in the two study groups. The primary outcome was the ED90 for desirable uterine tone based on the opinion of the in-charge obstetrician. The number of subjects receiving supplemental uterotonics was compared.
Results: In the low-risk group, three (3.7%), out of the 41 parturients, did not achieve a satisfactory suitable response to OX dose of 9; on the other hand, 24 high-risk parturients (58%) did not achieve a satisfactory and reasonable response to OX dose of 9. The OX ED90 was significantly greater for the high risk-group (11.55 units, 10.39-14.86) than the low-risk group (8.13 units, 8.31-9.56). Fisher’s exact probability test showed a significant difference in ED90 of OX between the two groups (P=0.02).
Conclusion: The present study results showed that the mean ED90 of OX in low-risk parturients was significantly lower than that of high-risk ones. We suggest differentiation between low-risk and high-risk parturients in the guidelines of OX administration.
Methods: This experimental study was a single-blind and dose-response study using a 9:1 biased-coin sequential allocation method to estimate the ED90 of prophylactic infusion of OX in women with high and low risk for uterine atony who underwent CS. The total administrated OX dose of each patient was determined in the two study groups. The primary outcome was the ED90 for desirable uterine tone based on the opinion of the in-charge obstetrician. The number of subjects receiving supplemental uterotonics was compared.
Results: In the low-risk group, three (3.7%), out of the 41 parturients, did not achieve a satisfactory suitable response to OX dose of 9; on the other hand, 24 high-risk parturients (58%) did not achieve a satisfactory and reasonable response to OX dose of 9. The OX ED90 was significantly greater for the high risk-group (11.55 units, 10.39-14.86) than the low-risk group (8.13 units, 8.31-9.56). Fisher’s exact probability test showed a significant difference in ED90 of OX between the two groups (P=0.02).
Conclusion: The present study results showed that the mean ED90 of OX in low-risk parturients was significantly lower than that of high-risk ones. We suggest differentiation between low-risk and high-risk parturients in the guidelines of OX administration.
Systematic Review: Original Research |
Subject:
Anesthesia
Received: 2021/09/11 | Accepted: 2021/11/16 | Published: 2022/03/14
Received: 2021/09/11 | Accepted: 2021/11/16 | Published: 2022/03/14
References
1. Begum T, Rahman A, Herfina Nababan DM, Hoque E, Al Fazal Khan TA, Anwar I. Indications and determinants of caesarean section delivery: Evidence from a population-based study in Matlab, Bangladesh. PLoS ONE. 2017;12(11):e0188074. [DOI:10.1371/journal.pone.0188074] [PMID] [PMCID]
2. Festin MR, Laopaiboon M, Pattanittum P, Ewens MR, Henderson-Smart DJ, Crowther CA, et al. Caesarean section in four South East Asian countries: reasons for, rates, associated care practices and health outcomes. BMC Pregnancy and Childbirth. 2009;9:17. [DOI:10.1186/1471-2393-9-17] [PMID] [PMCID]
3. Sheehan SR, Montgomery AA, Carey M, McAuliffe FM, Eogan M, Gleeson R, et al. Oxytocin bolus versus oxytocin bolus and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial. BMJ (Clinical research ed). 2011;343:d4661. [DOI:10.1136/bmj.d4661] [PMID] [PMCID]
4. Firmin M, Carles G, Mence B, Madhusudan N, Faurous E, Jolivet A. Postpartum hemorrhage: incidence, risk factors, and causes in Western French Guiana. Journal of gynecology obstetrics and human reproduction. 2019;48(1):55-60. [DOI:10.1016/j.jogoh.2018.11.006] [PMID]
5. Breathnach F, Geary M, editors. Uterine atony: definition, prevention, nonsurgical management, and uterine tamponade. Seminars in perinatology; 2009: Elsevier. [DOI:10.1053/j.semperi.2008.12.001] [PMID]
6. Devikarani D, Harsoor S. Are we using right dose of oxytocin? Indian journal of Anaesthesia. 2010;54(5):371. [DOI:10.4103/0019-5049.71020] [PMID] [PMCID]
7. No G-tG. Prevention and management of postpartum haemorrhage. BJOG. 2016;124:e106-e49. [DOI:10.1111/1471-0528.14178] [PMID]
8. Rosseland LA, Hauge TH, Grindheim G, Stubhaug A, Langesæter E. Changes in Blood Pressure and Cardiac Output during Cesarean DeliveryThe Effects of Oxytocin and Carbetocin Compared with Placebo. The Journal of the American Society of Anesthesiologists. 2013;119(3):541-51. [DOI:10.1097/ALN.0b013e31829416dd] [PMID]
9. Svanström M, Biber B, Hanes M, Johansson G, Näslund U, Bålfors E. Signs of myocardial ischaemia after injection of oxytocin: a randomized double-blind comparison of oxytocin and methylergometrine during Caesarean section. British journal of anaesthesia. 2008;100(5):683-9. [DOI:10.1093/bja/aen071] [PMID]
10. Dyer RA, Butwick AJ, Carvalho B. Oxytocin for labour and caesarean delivery: implications for the anaesthesiologist. Current Opinion in Anesthesiology. 2011;24(3):255-61. [DOI:10.1097/ACO.0b013e328345331c] [PMID]
11. Lavoie A, McCarthy RJ, Wong CA. The ED90 of prophylactic oxytocin infusion after delivery of the placenta during cesarean delivery in laboring compared with nonlaboring women: an up-down sequential allocation dose-response study. Anesthesia & Analgesia. 2015;121(1):159-64. [DOI:10.1213/ANE.0000000000000781] [PMID]
12. Biguzzi E, Franchi F, Ambrogi F, Ibrahim B, Bucciarelli P, Acaia B, et al. Risk factors for postpartum hemorrhage in a cohort of 6011 Italian women. Thrombosis research. 2012;129(4):e1-e7. [DOI:10.1016/j.thromres.2011.09.010] [PMID]
13. Oyelese Y, Ananth CV. Postpartum hemorrhage: epidemiology, risk factors, and causes. Clinical obstetrics and gynecology. 2010;53(1):147-56. [DOI:10.1097/GRF.0b013e3181cc406d] [PMID]
14. Ende HB, Lozada MJ, Chestnut DH, Osmundson SS, Walden RL, Shotwell MS, et al. Risk Factors for Atonic Postpartum Hemorrhage: A Systematic Review and Meta-Analysis. Obstetrics & Gynecology. 2021;137(2):305-23. [DOI:10.1097/AOG.0000000000004228] [PMID] [PMCID]
15. Kovacheva VP, Soens MA, Tsen LC. A randomized, double-blinded trial of a "rule of threes" algorithm versus continuous infusion of oxytocin during elective cesarean delivery. Anesthesiology. 2015;123(1):92-100. [DOI:10.1097/ALN.0000000000000682] [PMID]
16. George RB, McKeen D, Chaplin AC, McLeod L. Up-down determination of the ED 90 of oxytocin infusions for the prevention of postpartum uterine atony in parturients undergoing Cesarean delivery. Canadian Journal of Anesthesia/Journal canadien d'anesthésie. 2010;57(6):578-82. [DOI:10.1007/s12630-010-9297-1] [PMID]
17. Kaur H, Bala R, Gupta N. A study to determine minimum effective dose of oxytocin infusion during caesarean delivery in parturients at high risk of uterine atony. Journal of Obstetric Anaesthesia and Critical Care. 2017;7(2):75. [DOI:10.4103/joacc.JOACC_42_16]
18. Balki M, Ronayne M, Davies S, Fallah S, Windrim R, Carvalho JC. Minimum oxytocin dose requirement after cesarean delivery for labor arrest. Obstetrics & Gynecology. 2006;107(1):45-50. [DOI:10.1097/01.AOG.0000191529.52596.c0] [PMID]
19. Tsen LC, Balki M. Oxytocin protocols during cesarean delivery: time to acknowledge the risk/benefit ratio? International journal of obstetric anesthesia. 2010;19(3):243-5. [DOI:10.1016/j.ijoa.2010.05.001] [PMID]
20. Ding C, Leow MS, Magkos F. Oxytocin in metabolic homeostasis: implications for obesity and diabetes management. Obesity Reviews. 2019;20(1):22-40. [DOI:10.1111/obr.12757] [PMID] [PMCID]
21. Fan X, Xu T, Ding H, Li H, Yang Y, He Y, et al. DNA methylation‐reprogrammed oxytocin receptor underlies insensitivity to oxytocin in pre‐eclamptic placental vasculature. Journal of Cellular and Molecular Medicine. 2019;23(6):4118-26. [DOI:10.1111/jcmm.14299] [PMID] [PMCID]
22. Zackler A, Flood P, Dajao R, Maramara L, Goetzl L. Suspected chorioamnionitis and myometrial contractility: mechanisms for increased risk of cesarean delivery and postpartum hemorrhage. Reproductive Sciences. 2019;26(2):178-83. [DOI:10.1177/1933719118778819] [PMID]
| Rights and permissions | |
 |
Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/. |